Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5187882 | 0.84 | KMT2A (0.51) | KMT2AHPGDSMN1; SMN2NPC1MEN1 | |
| SCHEMBL491221 | 0.77 | PTPN2 (0.43) | KMT2AHPGDNPC1MEN1L3MBTL1 | |
| SCHEMBL31097077 | 0.76 | BCAT2 (0.46) | KMT2ASMN1; SMN2NPC1MEN1KDM4E | |
| SCHEMBL15286465 | 0.74 | KMT2A (0.50) | KMT2AHPGDSMN1; SMN2NPC1MEN1 | |
| SCHEMBL15295277 | 0.74 | KMT2A (0.50) | KMT2AHPGDSMN1; SMN2NPC1MEN1 | |
| SCHEMBL4749594 | 0.73 | SMN1; SMN2 (0.64) | KMT2AHPGDSMN1; SMN2NPC1MEN1 | |
| SCHEMBL70575 | 0.73 | KMT2A (0.56) | KMT2AHPGDSMN1; SMN2NPC1MEN1 | |
| SCHEMBL157777 | 0.73 | HPGD (0.70) | KMT2AHPGDSMN1; SMN2NPC1MEN1 | |
| SCHEMBL375957 | 0.73 | KMT2A (0.56) | KMT2AHPGDSMN1; SMN2NPC1MEN1 | |
| SCHEMBL538048 | 0.73 | NPC1 (0.63) | KMT2AHPGDSMN1; SMN2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111356695-B | Novel tricyclic compounds | 北京加科思新药研发有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-111356695-A | Novel tricyclic compounds | 北京加科思图新药研发有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-8222203-B2 | Macrocyclic oximyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222203-B2 | Macrocyclic oximyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009079352-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | SPINT2, HPN, PRSS1 | KMT2A 2340/4885HPGD 682/4885SMN1; SMN2 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.